Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Journal of the American Academy of Dermatology|August 10, 2018
Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitisAndrew Blauvelt, Eric L Simpson, Stephen K Tyring, et al.
Rheumatology (Oxford, England)|May 11, 2018
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomesMark C Genovese, Janet van Adelsberg, Chunpeng Fan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 29, 2020
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc AnalysisAnita Boyapati, Sergio Schwartzman, Jérôme Msihid, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 24, 2018
Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthmaJonathan Corren, Mario Castro, Pascal Chanez, et al.
RMD Open|March 23, 2017
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitorsVibeke Strand, Matthew Reaney, Chieh-I Chen, et al.
Allergy|November 30, 2018
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposisKarin Jonstam, Brian N Swanson, Leda P Mannent, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 26, 2021
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseasesJennifer D Hamilton, Sivan Harel, Brian N Swanson, et al.
Journal of the American Association of Nurse Practitioners|September 14, 2018
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trialsSusan J Tofte, Kim Papp, Neil Sadick, et al.
The Lancet. Respiratory Medicine|June 28, 2021
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysisWilliam W Busse, Sally E Wenzel, Thomas B Casale, et al.
The British Journal of Dermatology|December 2, 2017
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)M de Bruin-Weller, D Thaçi, C H Smith, et al.
Pageof 8